IRBESARTAN IN THE CLINICAL PRACTICE
https://doi.org/10.20996/1819-6446-2014-10-6-659-664
Abstract
Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.
About the Authors
V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
A. I. Tarzimanova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
References
1. Shalnova S, Kukushkin S., Manoshkina E. et al. Hypertension and adherence to therapy. Vrach 2009; 12: 39-42. Russian (Шальнова С., Кукушкин С., Маношкина Е. и др. Артериальная гипертензия и приверженность к терапии. Врач 2009; 12: 39-42).
2. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet, 2001; 358:1682-6.
3. National guidelines for the diagnosis and treatment of hypertension (4th revision). Sistemnye Gipertenzii 2010 (3): 5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).
4. ESH-ESC Guidelines Committee. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertension 2013; 31: 1281-357.
5. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
6. Munger MA. Angiotensin receptor blocker therapy and cardiovascular protection. Modern evidence base and prospects. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (7): 93-104. Russian (Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваскулярная Терапия и Профилактика 2011; 10(7): 93-104).
7. Fogari R, Ambrosoli S, Corradi L, et al. Irbesartan Multicenter Investigator’s Group. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15 (12-1): 1511-8.
8. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16 (8): 569-75.
9. Mimran A, Ruilope L, Kerwin L et al. A rindomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12 (3): 203-8.
10. Larochelle P, Flack JM, Marbury TC и др. Irbesartan Multicenter Investigators. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol 1997; 80 (12): 1613-5.
11. Chazova IE. New European guidelines for the management of patients with hypertension: a place sartans. Sistemnye Gipertenzii 2008; 2: 4-7. Russian (Чазова И.Е. Новые Европейские рекомендации по ведению пациентов с артериальной гипертонией: место сартанов. Системные Гипертензии 2008; 2: 4-7).
12. Ostroumova OD, Shchukina GN, Fomina VM. The antihypertensive efficacy of irbesartan. Sistemnye Gipertenzii 2011; 4: 16-21. Russian (Остроумова О.Д., Щукина Г.Н., Фомина В.М. Антигипертензивная эффективность ирбесартана. Системные Гипертензии 2011; 4: 16-21).
13. Kassler-Taub K, Littlejohn T, Elliot W, et al. Irbesartan. Losartan Study Investigators. Comparative Efcacy of Two Angiotensin II Receptor Antagonist, Irbesartan and Losartan, in Mild-to-Moderate Hypertension. Am J Hypertens 1998; 11 (4-1): 445-53.
14. Mancia G, Korlipara K, van Possum P et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7 (2): 135-42.
15. Kjeldsen S, Naditch-Brule L, Perlini S et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardio-metabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064-70.
16. Malmqvist K, Kahan T, Edner M. et al. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol 2002;90(10): 1107-12.
17. Parving HH, Lehnert H, Bröchner-Mortensen J, et al.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8.
18. Lewis EJ et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12): 851-60.
Review
For citations:
Podzolkov V.I., Tarzimanova A.I. IRBESARTAN IN THE CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2014;10(6):659-664. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-6-659-664
Views:
846
Email this article 